-------------------------------Contact Information:Laurence Rosen, Esq.Phillip Kim, Esq.Kevin Chan, Esq.The Rosen Law Firm, P.A.275 Madison Avenue, 34 th FloorNew York, NY 10016Tel: (212) 686-1060Toll Free: (866) 767-3653Fax: (212) 202-3827 email@example.com firstname.lastname@example.org email@example.com www.rosenlegal.com
Rosen Law Firm, a global investor rights law firm, reminds purchasers of Seres Therapeutics, Inc. securities (NASDAQ:MCRB) from June 25, 2015 through July 29, 2016, both dates inclusive (the "Class Period") of the important November 28, 2016 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Seres Therapeutics investors under the federal securities laws. To join the Seres Therapeutics class action, go to the firm's website at http://rosenlegal.com/cases-961.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll free at 866-767-3653 or email firstname.lastname@example.org or email@example.com for more information on the class action. NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. According to the lawsuit, throughout the Class Period defendants issued false and misleading statements to investors that Seres Therapeutics advertised and hyped its lead drug product candidate SER-109 as "novel class of biological drugs" and a potential "first-in-field drug" despite knowledge that the Phase 2 clinical trial of SER-109 would fail to achieve its primary endpoint as compared to placebo. When the true details entered the market, the lawsuit claims that investors suffered damages. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 28, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to the firm's website at http://rosenlegal.com/cases-961.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via email at firstname.lastname@example.org or email@example.com. Attorney Advertising. Prior results do not guarantee a similar outcome. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm. Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.